Actively Recruiting
Observational Study of Ribociclib Combined With Hormone Therapy for HRHER2- Early Breast Cancer in Men and Women in Saudi Arabia
Led by Novartis Pharmaceuticals · Updated on 2026-07-06
177
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing the use of ribociclib combined with adjuvant endocrine therapy ET in patients with hormone receptor-positive, HER2-negative early breast cancer HRHER2- EBC in Saudi Arabia. This study includes premenopausal, perimenopausal, and postmenopausal women, as well as men, and aims to describe real-world effectiveness, safety, patient-reported outcomes PRO, and healthcare resource utilization HCRU data under routine clinical care. Patients who have started ribociclib treatment within 6 months prior to enrollment will be followed prospectively for 36 months. Data will be collected at baseline, 3, 6, 12, 24, and 36 months, aligning with routine follow-up visits. The study involves reviewing electronic medical records and collecting information on previous treatments, disease history, current treatment patterns, and outcomes without altering standard care decisions made by treating physicians. Participants will provide data through medical record review and routine clinical assessments, including monitoring adverse events, quality of life, and clinical characteristics such as menopausal status and cancer stage. The main outcome measured is invasive breast cancer-free survival at 36 months. All data will remain anonymized to protect patient privacy, and participation will not affect usual treatment or monitoring schedules.
CONDITIONS
Brief Title
RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here